AMOEBA (EPA:ALMIB) - AMOEBA: ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON JUNE 24 2020

Transparency directive : regulatory news

10/06/2020 17:45

PRESS RELEASE

Chassieu, 10 june 2020

  ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON JUNE 24 2020
    MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE

The General Meeting of Amoéba shareholders, convened on May 28, 2020 at 10 a.m.
at the Company's registered office, did not reach the quorum required to vote
on the ordinary and extraordinary resolutions.

Consequently, a new Ordinary and Extraordinary Shareholders' Meeting will be
held on second call on:

                        Wednesday 24 June 2020 - 10 am
   at the company registered office - 38 Avenue des Frères Montgolfier -
                              69680 CHASSIEU

for the purpose of ruling on the same agenda as the first convocation notice,
published in the Bulletin des Annonces Légales Obligatoires (BALO) of 13 may
2020.

The notice of the second convocation including the agenda was published in the
Bulletin des Annonces légales Obligatoires (BALO) of June 10, 2020. The terms
and conditions of participation and voting at the Meeting are set out in this
notice.

Disclaimer

In the context of the coronavirus epidemic (COVID-19), traffic restrictions and
containment measures imposed by public authorities, the Board of Directors
decided, in accordance with the provisions of Ordinance No. 2020-321 of March
25, 2020 and Decree No. 2020-418 of April 10, 2020, that the Annual General
Meeting of AMOEBA  on Wednesday, June 24, 2020, will exceptionally be held
behind closed doors, without the presence of shareholders, at the Company's
registered office.

Under these conditions, shareholders are invited to participate in the
Shareholders' Meeting by using the postal voting form or by giving a proxy to
the Chairman.

The procedures for holding the Shareholders' Meeting may change depending on
health and/or legal requirements. Shareholders are invited to regularly consult
the section dedicated to the Shareholders' Meeting on the Company's website
http://www.amoeba-biocide.com/fr/
informations-reglementaireset-documents-financiers.

The results of the votes on the resolutions will be posted on the Company's
website.

The documents stipulated by article R.225-83 of the French commercial code are
available to shareholders from the moment that the assembly is convened, in
line with the applicable regulatory requirements:

* Any named shareholder can, until the fifth day (inclusive) before the
assembly, ask the company to send them these documents. For holders of bearer
shares, this right can only be exercised upon presentation of a statement of
participation in the accounts of bearer shares held by the authorised
intermediary;

* Any shareholder can consult these documents at the company's headquarters
during the 15 days
preceding the date of the assembly.

NEED MORE INFORMATION?

Find all the information you need to vote by post or give proxy to the Chairman
on our dedicated page:
http://www.amoeba-biocide.com/fr/assemblee-generale-du-24-juin-2020

Download : le bulletin de vote par correspondance ( the postal voting)
le guide du vote par correspondance (the guide to voting by correspondence)

We are at your disposal to provide you with any additional information on
voting procedures by calling
+ 33 (0)1 53 65 68 68 or by email at amoeba@calyptus.net

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE General Manager
+33 (0)4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors and Media Relations
Grégory BOSSON / Mathieu CALLEUX
Agence Calyptus
+33(0)1 53 65 37 90
gregory.bosson@calyptus.net

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOEBA: ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON JUNE 24 2020

Transparency directive : regulatory news

AMOEBA's latest news

Other stories